FDA Recalls Cardioplegia Solution for Sterility Assurance Failure
Central Admixture Pharmacy Services is recalling cardioplegia solution due to sterility assurance concerns identified in an FDA inspection. The recall affects 269 bags distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. Per the severity rubric, this qualifies as a risk-of-harm product (sterile injectable for cardiac use) where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc., of Allentown, Pennsylvania, is recalling Cardioplegia Solution, Maintenance 4:1 low potassium formulation (810 mL per bag, NDC 71285-0103-1) due to a lack of assurance of product sterility. An FDA inspection raised concerns about whether the product met sterility requirements.
Cardioplegia solution is a sterile injectable product used during cardiac surgery. The recall affects 269 bags distributed nationwide. The affected lots are: 37-893803 (expires 04/28/2023), 37-896483 (expires 05/07/2023), 37-897939 (expires 05/13/2023), and 37-900952 (expires 05/26/2023).
Healthcare providers who have this product should contact Central Admixture Pharmacy Services, Inc., for guidance regarding the recalled product.
The recalled product
- Product
- Cardioplegia Solution, Maintenance 4:1 low potassium, 20 mEq K, packaged in 810 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., Lehigh Valley, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-0103-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable Pharmaceutical
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot # 37-893803
- Exp 04/28/2023
- 37-896483
- Exp 05/07/2023
- 37-897939
- Exp 05/13/2023
- 37-900952
- Exp 05/26/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27